CN1518595A - 修饰的精氨酸脱亚胺酶 - Google Patents

修饰的精氨酸脱亚胺酶 Download PDF

Info

Publication number
CN1518595A
CN1518595A CNA01819673XA CN01819673A CN1518595A CN 1518595 A CN1518595 A CN 1518595A CN A01819673X A CNA01819673X A CN A01819673XA CN 01819673 A CN01819673 A CN 01819673A CN 1518595 A CN1518595 A CN 1518595A
Authority
CN
China
Prior art keywords
leu
glu
ile
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA01819673XA
Other languages
English (en)
Chinese (zh)
Inventor
迈克・A・克拉克
迈克·A·克拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenix Pharmacologics Inc
Original Assignee
PHONENIX PHARMACOLOGICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/723,546 external-priority patent/US6737259B1/en
Application filed by PHONENIX PHARMACOLOGICS Inc filed Critical PHONENIX PHARMACOLOGICS Inc
Publication of CN1518595A publication Critical patent/CN1518595A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CNA01819673XA 2000-11-28 2001-09-19 修饰的精氨酸脱亚胺酶 Pending CN1518595A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/723,546 US6737259B1 (en) 1997-05-12 2000-11-28 Modified arginine deiminase
US09/723,546 2000-11-28

Publications (1)

Publication Number Publication Date
CN1518595A true CN1518595A (zh) 2004-08-04

Family

ID=24906720

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA01819673XA Pending CN1518595A (zh) 2000-11-28 2001-09-19 修饰的精氨酸脱亚胺酶

Country Status (7)

Country Link
EP (1) EP1337630A2 (fr)
JP (1) JP2004515232A (fr)
KR (1) KR20040004449A (fr)
CN (1) CN1518595A (fr)
AU (1) AU2001289132A1 (fr)
CA (1) CA2430077A1 (fr)
WO (1) WO2002044360A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101002945A (zh) * 2006-01-20 2007-07-25 清华大学 一种用于肿瘤治疗的新型复合物
WO2007082483A1 (fr) * 2006-01-20 2007-07-26 Tsinghua University Médicament pour le traitement de tumeurs et son utilisation
CN101812438A (zh) * 2010-03-25 2010-08-25 江苏泰康生物医药有限公司 一种精氨酸脱亚氨酶突变体及其制备与应用
CN102703339A (zh) * 2011-08-29 2012-10-03 山东恩贝生物工程有限公司 高产精氨酸脱亚胺酶菌株及用它生产l-瓜氨酸的方法
CN106794229A (zh) * 2014-03-18 2017-05-31 瑞华药业集团 工程化嵌合聚乙二醇化adi和使用方法
CN108265044A (zh) * 2016-12-31 2018-07-10 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN110121340A (zh) * 2016-11-02 2019-08-13 波拉里集团 聚乙二醇化精氨酸脱亚氨酶的调配物
CN110167955A (zh) * 2016-09-29 2019-08-23 梅哈里医学院 细菌抑制剂
CN111818937A (zh) * 2017-11-30 2020-10-23 爵士制药爱尔兰有限公司 使用天冬酰胺酶的治疗方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
RU2335539C2 (ru) * 2002-06-20 2008-10-10 Байо-Кэнсер Тритмент Интернэшнл Лимитид Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации
EP1599217B1 (fr) * 2002-11-18 2014-04-16 Polaris Group Methodes d'inhibition d'une replication virale in vivo
WO2005107815A2 (fr) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Dérivés de polymères comprenant un point de ramification de type imide
WO2006015512A1 (fr) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Arginine déiminase modifiée
FR2884717B1 (fr) * 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
TW201611843A (en) * 2012-04-04 2016-04-01 Polaris Group Methods of treatment with arginine deiminase
ES2805360T3 (es) 2013-03-15 2021-02-11 Tdw Group Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer
TWI775160B (zh) 2014-09-16 2022-08-21 開曼群島商瑞華藥業集團 用於治療癌症之與adi-peg 20抗體具有降低之交叉反應性的精胺酸脫亞胺酶
CN106591270B (zh) * 2017-01-23 2018-09-21 江南大学 一株定点突变改造的基因工程精氨酸脱亚胺酶

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3209338B2 (ja) * 1990-09-10 2001-09-17 株式会社ジャパンエナジー ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101405019B (zh) * 2006-01-20 2014-06-04 清华大学 一种治疗肿瘤的药物及其应用
WO2007082482A1 (fr) * 2006-01-20 2007-07-26 Tsinghua University Nouveau composé de traitement de tumeur
CN101002945A (zh) * 2006-01-20 2007-07-25 清华大学 一种用于肿瘤治疗的新型复合物
WO2007082483A1 (fr) * 2006-01-20 2007-07-26 Tsinghua University Médicament pour le traitement de tumeurs et son utilisation
AU2007207267B2 (en) * 2006-01-20 2012-06-28 Protgen Ltd. Novel compound for treatment of tumor
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN101812438A (zh) * 2010-03-25 2010-08-25 江苏泰康生物医药有限公司 一种精氨酸脱亚氨酶突变体及其制备与应用
CN101812438B (zh) * 2010-03-25 2014-08-27 江苏泰康生物医药有限公司 一种精氨酸脱亚氨酶突变体及其制备与应用
CN102703339A (zh) * 2011-08-29 2012-10-03 山东恩贝生物工程有限公司 高产精氨酸脱亚胺酶菌株及用它生产l-瓜氨酸的方法
CN102703339B (zh) * 2011-08-29 2013-08-14 山东恩贝生物工程有限公司 高产精氨酸脱亚胺酶菌株及用它生产l-瓜氨酸的方法
CN106794229A (zh) * 2014-03-18 2017-05-31 瑞华药业集团 工程化嵌合聚乙二醇化adi和使用方法
CN106794229B (zh) * 2014-03-18 2020-12-18 瑞华药业集团 工程化嵌合聚乙二醇化adi和使用方法
CN110167955B (zh) * 2016-09-29 2024-04-02 梅哈里医学院 细菌抑制剂
CN110167955A (zh) * 2016-09-29 2019-08-23 梅哈里医学院 细菌抑制剂
CN110121340A (zh) * 2016-11-02 2019-08-13 波拉里集团 聚乙二醇化精氨酸脱亚氨酶的调配物
CN108265044A (zh) * 2016-12-31 2018-07-10 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN111818937A (zh) * 2017-11-30 2020-10-23 爵士制药爱尔兰有限公司 使用天冬酰胺酶的治疗方法

Also Published As

Publication number Publication date
JP2004515232A (ja) 2004-05-27
WO2002044360A2 (fr) 2002-06-06
AU2001289132A1 (en) 2002-06-11
KR20040004449A (ko) 2004-01-13
WO2002044360A3 (fr) 2002-12-19
CA2430077A1 (fr) 2002-06-06
EP1337630A2 (fr) 2003-08-27

Similar Documents

Publication Publication Date Title
CN1518595A (zh) 修饰的精氨酸脱亚胺酶
CN1163594C (zh) 体外造血细胞的刺激
CN1323345A (zh) 具有降低的免疫应答的修饰多肽
CN1038035C (zh) 聚乙二醇蛋白质结合物的制备方法
CN1093881C (zh) 免疫原或诊断剂的制备及其获得免疫原或诊断试剂的方法
CN1151252C (zh) 生产微生物转谷氨酰胺酶的方法
CN1322243A (zh) 尿酸氧化酶
CN1549826A (zh) 治疗糖尿病的组合物和方法
CN1918176A (zh) 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
CN1217724A (zh) 降钙素片段的重组制备方法和其在制备降钙素和相关类似物中的用途
CN1809378A (zh) 体内抑制病毒复制的方法
CN1723041A (zh) 包含抗原性杂络物的稳定的免疫原性产物
CN1636058A (zh) 新型丙氨酸转氨酶及其应用方法
CN1203173C (zh) 转谷氨酰胺酶的制备方法
CN1314806C (zh) 小型化抗eb病毒肿瘤多肽及其应用与制备方法
CN1839152A (zh) 包含或缺乏CD11b/CD18相互作用结构域的修饰的博德特氏菌腺苷酸环化酶及其用途
CN1229498C (zh) 重组的核糖核酸酶蛋白质
CN1810970A (zh) 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
CN1642570A (zh) 含吸因子ⅷ的稳定药物组合物
CN1929860A (zh) HIV gp41衍生肽的位点特异性化学修饰
CN1531549A (zh) 分泌性细菌效应蛋白的药物用途
CN1161468C (zh) Mpl配体类似物
CN1260353C (zh) 用于治疗细菌感染的多价噬菌体制备方法
CN1285381C (zh) 多发性硬化症治疗中所用的趋化因子突变体
CN1057124C (zh) 具改进纤溶特性和凝血酶抑制活性的双功能尿激酶变异体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: DERUI NEW DRUG R & D CO., LTD.

Free format text: FORMER OWNER: PHOENIX PHARMACOLOGICS INC.

Effective date: 20050325

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20050325

Address after: American California

Applicant after: Phoenix Pharmacologics Inc.

Address before: American Pennsylvania

Applicant before: Phonenix Pharmacologics, Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068646

Country of ref document: HK

AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1068646

Country of ref document: HK